Advanced search
Publication Cover
Expert Review of Hematology Volume 13, 2020 - Issue 4
Submit an article Journal homepage
10,132
Views
30
CrossRef citations to date
0
Altmetric
Original Research

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

Ajai ChariDepartment of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-0405-7480View further author information
ORCID Icon,
Paul G. RichardsonJerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Dorothy RomanusGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Meletios A. DimopoulosHematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, GreeceORCID Iconhttps://orcid.org/0000-0001-8990-3254View further author information
ORCID Icon,
Pieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-0808-2237View further author information
ORCID Icon,
Evangelos TerposHematology & Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, GreeceORCID Iconhttps://orcid.org/0000-0001-5133-1422View further author information
ORCID Icon,
Roman HajekUniversity Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech RepublicView further author information
,
Aditya RajuScientific Consulting, Xcenda, Palm Harbor, FL, USAView further author information
,
Antonio PalumboGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Lauren E. CainGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Marlo BlazerScientific Consulting, Xcenda, Palm Harbor, FL, USAView further author information
,
Hui HuangGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Eileen FarrellyScientific Consulting, Xcenda, Palm Harbor, FL, USAView further author information
&
Sikander AilawadhiDivision of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, United StatesCorrespondence[email protected]
View further author information
 show all
Pages 421-433 | Received 17 Jan 2020, Accepted 11 Feb 2020, Published online: 09 Mar 2020

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.